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MT-III, a snake venom GIIA sPLA2, which shares structural and functional features with mammalian GIIA sPLA2s, activates
macrophage defense functions including lipid droplet (LDs) formation, organelle involved in both lipid metabolism and
inﬂammatory processes. Macrophages (MΦs) loaded with LDs, termed foam cells, characterize early blood vessel fatty-streak
lesions during atherosclerosis. However, the factors involved in foam cell formation induced by a GIIA sPLA2 are still unknown.
Here, we investigated the participation of lipid homeostasis-related factors in LD formation induced by MT-III in macrophages.
We found that MT-III activated PPAR-γ and PPAR-β/δ and increased the protein levels of both transcription factors and CD36
in macrophages. Pharmacological interventions evidenced that PPAR-γ, PPAR-β/δ, and CD36 as well as the endoplasmic
reticulum enzymes ACAT and DGAT are essential for LD formation. Moreover, PPAR-β/δ, but not PPAR-γ, is involved in
MT-III-induced PLIN2 protein expression, and both PPAR-β/δ and PPAR-γ upregulated CD36 protein expression, which
contributes to MT-III-induced COX-2 expression. Furthermore, production of 15-d-PGJ2, an activator of PPARs, induced by
MT-III, was dependent on COX-1 being LDs an important platform for generation of this mediator.
1. Introduction
Secreted PLA2 (sPLA2) enzymes comprise the largest
family of PLA2s and comprise 12 isoforms subdivided in
structural collections I/II/V/X and two other atypical
structural collections (III and XII) [1, 2]. sPLA2-IIA is
often referred as the inﬂammatory sPLA2, but the molecu-
lar mechanism underlying its proinﬂammatory action is
not fully understood. These enzymes are able to release
fatty acids from cell membranes, leading to subsequent
production of lipid mediators. Distinct and unique roles
of these enzymes in diverse biological events, including
digestion, host defense, reproduction, and development of
inﬂammatory diseases and metabolic disorders, have been
described [2].
sPLA2s are major protein components of Bothrops snake
venoms and are classiﬁed into groups I and II, according to
their biochemical and structural characteristics. Noteworthy,
sPLA2s from Bothrops snake venoms share structural and
functional features with mammalian inﬂammatory GIIA
sPLA2s, which are found in high concentrations in
inﬂammatory exudates [3, 4]. Our group has previously
demonstrated that an Asp49 sPLA2, named myotoxin-III
(MT-III), isolated from Bothrops asper snake venom, acti-
vates inﬂammatory functions of macrophages, including
formation of lipid droplets (LDs) and upregulation of
perilipin 2 (PLIN2), a scaﬀold protein involved in LD
assembly and macrophage diﬀerentiation into foam cells
[5–7]. However, the mechanisms involved in foam cell
formation induced by sPLA2 MT-III are still unclear.
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LDs are cytoplasmic organelles, present in high levels in
foam cells, that are comprised by a hydrophobic core of neu-
tral lipids (triglycerides and cholesterol esters) surrounded by
a phospholipid monolayer and a growing list of associated
proteins [7–9]. LDs are found in inﬂammatory leukocytes
and described as rich deposits of esteriﬁed arachidonic acid
(AA), a precursor of eicosanoids, and enzymes necessary
for their synthesis, including cyclooxygenases (COX) and
prostaglandin E2 synthase [10]. The biogenesis of LDs is a
tightly regulated process in which lipid homeostasis-related
transcription factors, such as peroxisome proliferator-
activated receptors (PPARs), play a key role. Activated
PPARs upregulate the uptake of free fatty acids by increasing
the expression of the fatty acid transporter CD36 [11, 12] and
LD formation through increased expression of LD-associated
proteins, such as PLIN2. Upregulation of PPAR-γ and
PPAR-β/δ has been shown in foam macrophages [13], and
deletion of these transcription factors resulted in a decreased
number of LDs in cells stimulated with pathogens or free
fatty acids. However, the implication of these factors in foam
cell formation induced by group IIA secreted PLA2s remains
unknown. In addition, the endoplasmic reticulum (ER)
enzymes acyl-CoA:cholesterol acyltransferase (ACAT) and
diacylglycerol O-acyltransferase (DGAT), responsible for
the synthesis of cholesterol (ChE) and triacylglycerol
(TG), respectively, have also been associated with foam
cell formation in diverse pathological and inﬂammatory
conditions [14]. Due to the tight association between an
unbalanced lipid homeostasis and foam cell formation
seen in diverse inﬂammatory conditions, we investigated
the participation of distinct lipid homeostasis-related factors,
such as the transcription factors PPAR-γ and PPAR-β/δ, the
ER enzymes DGAT and ACAT, and CD36 scavenger recep-
tor in LD formation induced by the snake venom GIIA
sPLA2, MT-III, in macrophages.
2. Materials and Methods
2.1. Chemicals and Reagents. Heparin was obtained from
Roche Quimicos Farmaceuticos S.A. (Rio de Janeiro, S.A.,
Brazil) and Hema-3 stain from Biochemical Sciences (Swe-
desboro, NJ, USA). MTT and L-glutamine were obtained
from USB Thermo Fisher Scientiﬁc (Cleveland, OH, USA).
GW9662, GSK0660, and A922500 were purchased from
Merck KGaA (Darmstadt, HE, Germany). TMP-153 and
15-d-PGJ2 antibody were obtained from Cayman Chemical
(Ann Arbor, MI, USA). PPAR-γ and PPAR-β/δ antibodies
were purchased from Santa Cruz Biotechnology (Dallas,
TX, USA). CD36 antibody was obtained from R&D Systems
(Minneapolis, MN, EUA). 15-deoxy-Δ12,14-PGJ2 ELISA kit
was purchased from Enzo Life Sciences (Farmingdale, NY,
USA). E-toxate LAL kit, mouse mAb anti-β-actin, EDAC,
sulfo-N-succinimidyl oleate (SSO), and Nile Red were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Secondary
antibodies, anti-mouse and anti-guinea pig, conjugated to
HRP and nitrocellulose membrane, were obtained from GE
Healthcare (Buckinghamshire, UK). Gentamicin was pur-
chased from Schering-Plough (Whitehouse Station, NJ,
USA). DMSO and BSA were obtained from Amresco (Solon,
OH, USA). RPMI 1640, thiocarbohydrazide, and OsO4 were
purchased from Sigma-Aldrich (St. Louis, MO, USA). PLIN2
antibody, AlexaFluor 488 antibody, and iodide propidium
were purchased from Thermo Fisher Scientiﬁc (Sao Paulo,
S.P., Brazil). GA, TG, and all salts used were obtained from
Merck (Darmstadt, Germany). PFA was purchased from
Electron Microscopy Sciences (Hatﬁeld, PA, USA). Fluoro-
mont G was purchased from Molecular Probes (Eugene,
OR, USA). Donkey serum was obtained from Jackson Immu-
noResearch Laboratories (West Grove, PA, USA). Triton-X
was obtained from Union Carbide (Houston, TX, USA).
2.2. Animals. Male Swiss mice (18–20 g) were obtained from
Butantan Institute (São Paulo, Brazil). Animals were housed
in a temperature-controlled room (22–24°C) with a 12h
light-dark cycle and fresh water and food ad libitum. This
study was approved by the Butantan Institute Animal Exper-
imentation Ethics Committee (reference number 760/10) in
accordance with the procedures laid down by the Universities
Federation for Animal Welfare.
2.3. Phospholipase A2 (MT-III). MT-III was isolated from
Bothrops asper venom by ion-exchange chromatography
on CM-Sephadex C-25 using the conditions described
by Gutierrez and Lomonte [15] (veriﬁcar referência),
followed by RP-HPLC on a C8 semipreparative column
(10× 250mm; Vydac) eluted at 2.0mL/min with a 0–70%
acetonitrile gradient containing 0.1% (v/v) triﬂuoroacetic
acid, during 30min, on an Agilent 1200 instrument moni-
tored at 215nm. Homogeneity of the ﬁnal preparation
was assessed by analytical RP-HPLC on a C4 column
(4.6× 150mm) using a 0–60% acetonitrile gradient. The
absence of endotoxin contamination in the MT-III prepa-
ration was demonstrated by the quantitative Limulus ame-
bocyte lysate (LAL) test [16], which revealed undetectable
levels of endotoxin (<0.125EU/mL).
2.4. Harvesting of Macrophages. Peritoneal macrophages
were harvested from mice 4 days after i.p. injection of
1mL of 3% thioglycolate. Animals were killed under CO2
atmosphere, and cells were harvested by washing perito-
neal cavities with 3mL of PBS, pH7.2, containing 10 IU/
mL heparin. Aliquots of the washes were used for total cell
counts in a Neubauer chamber after dilution (1 : 20, v/v) in
Turk solution (0.2% crystal violet dye in 30% acetic acid).
To verify the predominance of macrophages in samples,
diﬀerential cell counts were performed on smears stained
with Hema3. More than 95% of the cell population con-
sisted of macrophages, as determined by conventional
morphological criteria. The remaining wash volumes were
centrifuged at 500×g for 6min (4°C), and the cell pellets
were used for subsequent studies after suitable dilutions.
2.5. Stimulation and Treatment of Macrophages. Macro-
phages were seeded on glass coverslips at a density of
2× 105 cells/coverslip and allowed to attach for 30min at
37°C under a 5% CO2 atmosphere. Nonadherent cells were
removed by washing with PBS. Cell monolayers were cul-
tured for 1 h in RPMI-1640 supplemented with 40μg/mL
gentamicin sulfate and 2mM L-glutamine at 37°C and 5%
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CO2 and were then challenged with MT-III (0.4μM) or
medium (control). This concentration of MT-III was selected
on the basis of the previous studies, since it induces the for-
mation of LDs in macrophages (Leiguez et al., [17]). Where
appropriate, the following inhibitors were used: GW9662
(10μM), inhibitor of PPAR-γ; GSK0660 (10μM), inhibitor
of PPAR-β/δ; SS0 (25μM), inhibitor of CD36; A922500
(100 nM), inhibitor of DGAT enzyme; and TMP-153
(100 nM), inhibitor of ACAT enzyme. All stock solutions
were prepared in DMSO and stored at −20°C. Aliquots were
diluted in RPMI-1640 to the required concentration immedi-
ately before use. The ﬁnal DMSO concentration was always
lower than 1% and had no eﬀect on lipid body numbers.
All pharmacological inhibitors were added between 30 and
60min before stimulation of macrophages with MT-III or
medium (control). Cells treated with the inhibitors were ana-
lyzed for viability by the tetrazolium-based (MTT) colori-
metric assay. No signiﬁcant changes in cell viability were
registered with any of the above agents or vehicle at the con-
centrations used (data not shown).
2.6. Lipid Droplet Staining and Quantiﬁcation. Analysis of
lipid droplet numbers was performed in osmium-stained
cells. In brief, macrophages (2× 105 cells) that adhered to
glass coverslips were ﬁxed in 4% PFA in 0.1M phosphate
buﬀer, pH7.2, for 15min and stained with OsO4. The cover-
slips were then rinsed in 0.1M phosphate buﬀer, stained in
1% OsO4 (30min), rinsed in deionized H2O, immersed in
1.0% thiocarbohydrazide (5min), rinsed again in 0.1M phos-
phate buﬀer, restained with 1% OsO4 (3min), rinsed with
H2O, and then dried and mounted. The morphology of the
ﬁxed cells was observed, and round osmiophilic structures
were identiﬁed as lipid droplets, which were then counted
under phase-contrast microscopy using the 100x objective
lens in 50 consecutively scanned leukocytes in each coverslip.
For assays with ﬂuorescent-labeled lipid droplets, macro-
phages (2× 105 cells) that adhered to glass coverslips were
incubated with Nile Red staining solution freshly prepared
in 0.1M phosphate buﬀer (10μg/mL) for 20min at room
temperature and washed with phosphate buﬀer. After several
washes, the coverslips were mounted with ﬂuoromont G
and examined under a ﬂuorescence microscope equipped
with the appropriate ﬁlter (Zeiss LSM 510 Meta, Dublin,
CA, USA).
2.7. Western Blotting. Aliquots of MT-III-stimulated and
nonstimulated cells (2× 106 cells) were lysed with 100μL of
sample buﬀer (0.5M Tris–HCl, pH6.8, 20% SDS, 1% glyc-
erol, 1M β-mercaptoethanol, and 0.1% bromophenol blue)
and boiled for 10min. Samples were resolved by SDS poly-
acrylamide gel electrophoresis (SDS-PAGE) on 10% bis-
acrylamide gels overlaid with a 5% stacking gel. Proteins were
then transferred to nitrocellulose membrane (GE Healthcare,
Buckinghamshire, UK) using a Mini Trans-Blot® (Bio-Rad
Laboratories, Richmond, CA, USA). The membranes were
blocked for 1 h with 5% nonfat dry milk in TTBS (20mM
Tris, 100mM NaCl, and 0.5% Tween 20) and incubated with
primary antibodies against PLIN2 (1 : 2000 dilution) or
PPAR-γ or PPAR-β/δ or CD36 (1 : 2000) and β-actin
(1 : 3000) for 1 h. They were then washed and incubated with
the appropriate secondary antibody conjugated to horserad-
ish peroxidase. Detection was made by the enhanced chemi-
luminescence (ECL) method according to the manufacturer’s
instructions (GE Healthcare, Buckinghamshire, UK). Band
densities were quantiﬁed with a GS-800 Densitometer (Bio-
Rad Laboratories, Richmond, CA) using the image analysis
software from Molecular Analyst® (Bio-Rad Laboratories,
Richmond, CA).
2.8. 15-d-PGJ2 Quantiﬁcation. Release of 15-d-PGJ2 was
determined by enzyme immunoassay using commercial kits.
In brief, 50μL aliquots of each sample were incubated with
the eicosanoids conjugated with acetylcholinesterase and
the speciﬁc rabbit antiserum in 96-well plates were coated
with anti-rabbit IgG mouse monoclonal antibody. After
addition of the substrate, the absorbance of the samples was
recorded at 405nm in a microplate reader (Labsystems
Multiskan), and concentrations of 15-d-PGJ2 were estimated
from standard curves.
2.9. Triacylglycerol and Cholesterol Quantiﬁcation. The
amounts of triacylglycerol and cholesterol/cholesterol ester
were measured using triacylglycerol or Cholesterol/Choles-
terol Ester Detection Kits according to the manufacturer’s
instructions (Abcam) in cells treated with medium or
MT-III.
2.10. Immunocytochemistry Analysis. Detection of 15-d-PGJ2
in MT-III-stimulated macrophages was performed by 15-d-
PGJ2 immunostaining. Cells were ﬁxed and permeabilized
in 1% EDAC [18] in calcium- and magnesium-free Hank’s
balanced salt solution (HBSSˉ/ˉ). The macrophages were
blocked with 0.5% normal donkey serum in 0.1M phosphate
buﬀer for 60min and then washed with HBSSˉ/ˉ and incu-
bated for 1 h with monoclonal antibodies against 15-d-PGJ2
(1 : 100). After further washes, the cells were incubated with
goat anti-rabbitAlexaFluor 488 (1 : 250) andNileRed solution
(1 : 250) for 1 h. The coverslips were then washed three times
and mounted with Fluoromount-G containing propidium
iodide (Invitrogen) and examined under a confocal laser scan-
ning microscope (Zeiss LSM 510 Meta, Dublin, CA, USA).
2.11. Statistical Analysis. Data are expressed as the mean
± standard error of mean (SEM) of at least three independent
experiments. Multiple comparisons among groups were
performed by one-way analysis of variance (ANOVA)
followed by Tukey’s test. Values of probability lower than
5% (p< 0.05) were considered signiﬁcant.
3. Results
3.1. PPAR-γ and PPAR-β/δ Contribute to LD Formation, but
Only PPAR-β/δ Is Involved in Increase of PLIN2 Protein
Expression in Macrophages Stimulated by MT-III. Participa-
tion of PPAR-γ and PPAR-β/δ in the signaling triggered by
fatty acids has been previously reported [19]. Therefore, the
involvement of these factors in MT-III-induced LD biogene-
sis was investigated using pharmacological approaches. The
eﬀects of selected pharmacological treatments were evaluated
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12 h after incubation of macrophages with MT-III. As seen in
Figure 1(a), pretreatment of cells with GW9662 (10μM), a
PPAR-γ antagonist, caused 74% reduction in the number of
LDs in MT-III-stimulated macrophages when compared
with vehicle-treated macrophages stimulated with MT-III.
However, pretreatment of cells with the PPAR-β/δ antago-
nist, GSK0660 abolished LD formation induced by MT-III
in macrophages when compared with vehicle-treated macro-
phages stimulated with MT-III. In an attempt to better
understand the involvement of PPAR-γ and PPAR-β/δ in
MT-III-induced LD formation, we further evaluated the con-
tribution of these transcription factors in PLIN2 protein
expression induced by MT-III. PLIN2 is a structural protein
implicated in LD assembly [5, 6] and transcriptionally con-
trolled by factors involved in lipid homeostasis, including
PPARs [11]. Figure 1(b) shows that PLIN2 protein expres-
sion was abolished in cells pretreated with the antagonist of
PPAR-β/δ GSK0660 and then stimulated with MT-III. How-
ever, the treatment of cells with GW9662 followed by incuba-
tion with MT-III did not alter PLIN2 protein expression
induced by this sPLA2. Altogether, these data indicate that
both PPAR-γ and PPAR-β/δ are involved in LD formation
stimulated by MT-III in macrophages while only PPAR-β/δ
acts by increasing PLIN2 protein expression.
3.2. MT-III Upregulates PPAR-γ and PPAR-β/δ Protein
Expression in Macrophages. As an additional mechanism
involved in lipid accumulation induced by MT-III in perito-
neal macrophages, we investigated the ability of MT-III to
upregulate PPAR-γ and PPAR-β/δ protein expression.
Levels of PPAR-γ and PPAR-β/δ protein expression were
analyzed by Western blot in cells stimulated with MT-III
or RPMI (control) for selected time intervals (1–24h). As
seen in Figure 2(a), levels of PPAR-γ protein expression
were increased in macrophages stimulated by MT-III in
all time windows evaluated (1–24h) when compared with
the corresponding controls. Similarly, Figure 2(b) shows
that MT-III increased PPAR-β/δ protein expression in
macrophages from 1 up to 24 h, compared to control cells.
Taken together, these data demonstrate the capacity of
MT-III to induce PPARγ and PPAR-β/δ protein expres-
sion in peritoneal macrophages.
3.3. MT-III Induces 15-d-PGJ2 Production via COX-1
Pathway and Activates PPAR-γ and PPAR-β/δ. It is known
that lipid mediators, mainly 15-d-PGJ2, are potent endoge-
nous activators of PPAR family [20, 21]. We then evaluated
the ability of MT-III to induce 15-d-PGJ2 production in
peritoneal macrophages. 15-d-PGJ2 levels were measured in
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Figure 1: Both PPAR-γ and PPAR-β/δ are involved in MT-III-induced LD formation in macrophages, but only PPAR-β/δ is required for
MT-III-induced PLIN2 protein expression in these cells. Peritoneal macrophages were incubated with GW9662 or GSK0660 (10 μM)
compounds for 1 h and then with MT-III (0.4 μM) for 12 h. (a) LDs were quantiﬁed using light microscopy after osmium staining. Each
bar represents the mean± SEM LDs/cell in 50 counted cells. Values represent means± SEM from 3–5 animals. ∗p < 0 05 compared with
control group; #p < 0 05 compared with vehicle-treated MT-III-stimulated cells. (b) Western blotting and densitometric analysis of the
band intensities of PLIN2 and β-actin (loading control) in macrophage extracts. The densities (in arbitrary units) were normalized with
those of β-actin. Results are expressed as mean± SEM from three experiments. ∗p < 0 05 compared with controls. #p < 0 05 compared
with vehicle-treated MT-III-stimulated cells.
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supernatants from macrophages incubated with MT-III
(0.4μM) or RPMI only (control). As shown in Figure 3(a),
incubation of macrophages withMT-III induced a signiﬁcant
increase in 15-d-PGJ2 production between 1 and 12h.
Maximal 15-d-PGJ2 production was observed after 12 h of
incubation with MT-III. These results reveal the capacity
of MT-III to induce 15-d-PGJ2 production in macro-
phages. Pretreatment of cells with COX-1 inhibitor valeryl
salicylate signiﬁcantly reduced 15-d-PGJ2 production while
pretreatment with COX-2 inhibitor, lumiracoxib, did not
aﬀect 15-d-PGJ2 production induced byMT-III (Figure 3(b)).
Therefore, 15-d-PGJ2 production is dependent on COX-
1, but not COX-2 pathway in macrophages stimulated
by MT-III.
To conﬁrm the activation of these factors by MT-III, an
immunoﬂuorescence assay was performed to evaluate trans-
location of PPAR-γ and PPAR-β/δ into the nucleus of
macrophages. As illustrated in Figure 3(c), macrophages
stimulated with RPMI (control) for 3 or 12h exhibited a ﬂuo-
rescent staining (green) for PPAR-γ, which did not colocalize
to nucleus staining (red). In macrophages stimulated with
MT-III (0.4μM) for 3 h, ﬂuorescent labeling for PPAR-γ
was seen colocalized in the nucleus, indicating translocation
of this factor to the nuclear region. Figure 3(d) illustrates
control macrophages incubated with RPMI (control) and
stained for PPAR-β/δ. In this condition, cells presented a
ﬂuorescent staining for PPAR-β/δ, with the absence of
colocalization with nucleus staining after 3 and 12 h of
incubation. However, incubation of cells with MT-III
(0.4μM) induced a strong staining for this factor, which
was colocalized with nucleus at 3 or 12 h of incubation,
evidencing translocation of this factor into cell nucleus.
3.4. MT-III-Induced LD Formation Is a Platform to 15-d-PGJ2
Production. LDs are lipid inclusions implicated in prostanoid
biosynthesis [10]. Considering the increased levels of 15-d-
PGJ2 in MT-III-stimulated macrophages, we hypothesize
that LDs could constitute a relevant site for production of
15-d-PGJ2. In order to investigate this hypothesis, macro-
phages stimulated with MT-III or RPMI (control) were incu-
bated with EDAC to immobilize the newly synthesized
eicosanoids [18] and immunostained with antibodies against
15-d-PGJ2. LDs were stained with Nile Red. As illustrated in
Figure 4, macrophages stimulated with MT-III (0.4μM)
for 12 h exhibited a (green) cytoplasmic staining pattern for
15-d-PGJ2. This same pattern was not observed in the
unstimulated control cells, which exhibited diﬀuse staining.
Fluorescent Nile Red-labeled LBs were also visualized 12h
after stimulation by MT-III and were absent in unstimulated
control macrophages. Overlapping images show that stained
cytoplasmic 15-d-PGJ2 matched perfectly with neutral lipid
inclusions in MT-III-stimulated macrophages indicating that
15-d-PGJ2 colocalizes to LDs. This demonstrates that MT-
III-induced LDs constitute cytoplasmic platforms involved
in 15-d-PGJ2 production.
3.5. Neutral Lipid Biosynthesis Is Relevant to MT-III-Induced
LD Formation. It has been demonstrated that activation of
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Figure 2: MT-III induces upregulation of PPAR-γ and PPAR-β/δ protein expression in macrophages. Peritoneal macrophages were
incubated with MT-III (0.4 μM) or RPMI (control) for 1, 6, 12, and 24 h. (a, b) Western blotting and densitometric analysis of the band
intensities of immunoreactive PPAR-γ (a) or PPAR-β/δ (b) and β-actin (loading control) in macrophage extracts. Results are expressed as
mean± SEM from three experiments. ∗p < 0 05 compared with controls.
5Mediators of Inﬂammation
1 6 12 24
⁎
⁎
⁎
+
0
20000
40000
60000
80000
15
-d
-P
G
J 2
 (p
g/
m
L)
MT-III
RPMI
(h)
(a)
VS LU
⁎
⁎
#
0
20000
40000
60000
80000
15
-d
-P
G
J 2
 (p
g/
m
L)
MT-III
RPMI
(b)
PPAR-훾 Nuclei Merged
RPMI
MT-III
3
RPMI
MT-III
12
10 휇m 10 휇m 10 휇m
10 휇m 10 휇m 10 휇m
10 휇m 10 휇m 10 휇m
10 휇m 10 휇m 10 휇m
(h
)
(c)
PPAR-훽/훿 Nuclei Merged
RPMI
MT-III
3
RPMI
MT-III
12
10 휇m 10 휇m 10 휇m
10 휇m 10 휇m 10 휇m
10 휇m 10 휇m 10 휇m
10 휇m 10 휇m 10 휇m
(h
)
(d)
Figure 3: MT-III induces 15-d-PGJ2 production dependent on COX-1 and COX-2. PPAR-γ and PPAR-β/δ are activated by MT-III.
(a) Quantiﬁcation of 15-d-PGJ2 in macrophage culture supernatants by speciﬁc EIA.
∗p < 0 05 compared with control group; +p < 0 05
as compared with MT-III-stimulated cells for 1 h. (b) Macrophages were pretreated with COX-1 (valeryl salicylate (VS)), 10μM, or
COX-2 (lumiracoxib (LU)) 10 μM inhibitors for 1 h before stimulation with MT-III (0.4 μM) for 6 h, and 15-d-PGJ2 production was
quantiﬁed by ELISA. ∗p < 0 05 compared with control group; #p < 0 05 compared with MT-III- stimulated cells. (c, d) Macrophages
incubated with RPMI (control) or MT-III (0.4 μM) for 3 or 12 h were labelled with anti-PPAR-γ (b) or PPAR-β/δ (d) conjugated to
Alexa 488 (green). Nuclei were stained with iodide propidium. The pictures are representative of three independent experiments.
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PPARs triggers an increase in enzymatic activity of enzymes
involved in neutral lipid synthesis [22]. DGAT and ACAT
are the main enzymes responsible for the synthesis of triacyl-
glycerol (TAG) and cholesterol (CE), respectively, both
present in LD core [23, 24]. Our results show that pre-
treatment of cells with A922500, a DGAT inhibitor, or
TMP-153, an ACAT inhibitor, abolished LD formation
induced by MT-III when compared with vehicle-treated
cells stimulated with MT-III (Figure 5(a)). As shown in
Figures 5(b) and 5(c), incubation of macrophages with
MT-III induced a signiﬁcant increase in levels of TAG
and CE, respectively, between 1 and 6h in comparison
with respective control cells. These results indicate the
involvement of DGAT and ACAT in MT-III-induced LD
formation and the composition of these lipid organelles.
3.6. CD36 Contributes to LD Formation and COX-2 Protein
Expression Induced by MT-III. Macrophages internalize
lipids by diﬀerent scavenger receptors, among which is
CD36. This receptor binds oxidized phospholipids/lipopro-
teins and long-chain fatty acids, leading to LD formation
and, as a consequence, to diﬀerentiation of macrophages
to foam cells during atherosclerotic processes [25, 26].
To verify the role of CD36 in LD formation induced by
MT-III, we evaluated the eﬀect of sulfosuccinimidyl oleate
compound (SSO), a CD36 antagonist, on MT-III-induced
LD formation. As shown in Figure 6(a), pretreatment of
macrophages with SSO (25μM) abolished LD formation
induced by MT-III in comparison with vehicle-treated
cells, stimulated with MT-III. This result indicates that
CD36 is relevant to MT-III-induced LD formation. Con-
sidering the relevance of CD36 to intracellular lipid accu-
mulation in macrophages, we next investigated whether
MT-III would increase the levels of CD36 in macrophages.
For this purpose, Western blotting analysis was performed,
in cells incubated and not incubated with MT-III or
medium (control) for 6, 12, and 24 h. This analysis revealed
a signiﬁcant increase of CD36 protein levels in cells stimu-
lated with MT-III from 6 up to 12 h, with a maximum level
seen at 6 hours of incubation, in comparison with the respec-
tive control (Figure 6(b)). Taken together, these data show
that CD36 scavenger receptor is an important factor involved
in LD formation in cells stimulated by MT-III. Therefore,
upregulation of CD36 expression can be an additional
mechanism implicated in lipid accumulation induced by
MT-III in macrophages. Considering CD36 a superﬁcial
membrane receptor, we investigate the contribution of this
receptor in the activation of COX-2 pathway in macro-
phages stimulated by MT-III. As shown in Figure 6(c),
pretreatment of macrophages with SSO (25μM) reduced
the protein expression of COX-2 induced by MT-III in
comparison with vehicle-treated cells and stimulated with
MT-III. This result indicates that CD36 is relevant to
MT-III-induced COX-2 protein expression.
3.7. Upregulation of CD36 Protein Expression Is Regulated
by PPAR-γ and PPAR-β/δ Activation in Macrophages
Stimulated by MT-III. Considering the relevance of CD36
receptor to metabolism and accumulation of lipids in
macrophages and previous reports demonstrating that this
receptor is under transcriptional control of PPAR family
[27], we evaluated the participation of PPAR-γ and PPAR-
β/δ in the upregulation of CD36 expression induced by
MT-III. Pretreatment of cells with either GW9662 (PPAR-γ
antagonist) or GSK0660 (PPAR-β/δ antagonist) abolished
the increase of CD36 protein expression caused by MT-
III in comparison with vehicle-treated cells stimulated
with MT-III (Figure 7). These data indicate that the
increase of levels of CD36 protein expression induced by
MT-III in macrophages is dependent on PPAR-γ and
PPAR-β/δ activation.
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Figure 4: MT-III-induced LDs compartmentalize 15-d-PGJ2 in peritoneal macrophages. Macrophages incubated with RPMI (control) or
MT-III (0.4 μM) for 12 h were labeled for LDs (Nile Red) and for 15-d-PGJ2 (anti-15-d-PGJ2 antibody, Enzo Life Sciences). The merged
image shows colocalization of 15-d-PGJ2 to LDs. The pictures are representative of three independent experiments.
7Mediators of Inﬂammation
4. Discussion
Lipid accumulation in monocytes and macrophages is
responsible for diﬀerentiation of these cells into foam cells
and represents a key step in the development of atherosclero-
sis [5, 28]. Therefore, these cells have been used as targets to
understand the inductors and mechanisms involved in ath-
erosclerotic process. Hereby, we demonstrated the activation,
expression, and contribution of diﬀerent factors involved in
lipid accumulation induced by MT-III, a group IIA sPLA2,
in phagocytic cells. Our results indicate that MT-III is able
to induce activation of PPAR-γ and PPAR-β/δ in macro-
phages, since both transcription factors were translocated
into nucleus in cells stimulated by this sPLA2. In the present
experimental conditions, translocation of PPAR-β/δ into the
nucleus was higher than that of PPAR-γ and showed a long-
term proﬁle. Considering that PPARs are activated by lipid
mediators and free fatty acids [29] and that arachidonic acid
(AA) was shown to activate PPAR-γ in alveolar macrophages
[30], the ability of MT-III to induce release of AA and other
polyunsatured fatty acids from macrophage membranes
[17, 31] may provide a favorable environment for activa-
tion of these factors. Although, activation of PPAR-γ and
PPAR-β/δ by LDL modiﬁed by a sPLA2 from Naja mos-
sambica snake venom has been reported in the literature
[32]; to our knowledge, this is the ﬁrst demonstration that
a group IIA sPLA2 per se induces activation of PPAR-γ
and PPAR-β/δ. The involvement of PPAR-γ and PPAR-
β/δ in LD formation and regulation of expression of
PLIN2, a protein involved in the uptake of fatty acids
and diﬀerentiation of macrophages into foam cells, have
been demonstrated in the literature [33–35]. Our ﬁndings
that inhibition of PPAR-β/δ abolished both LD formation
and PLIN2 protein expression induced by MT-III indicate
that PPAR-β/δ by regulating PLIN2 expression plays a
crucial role in LD formation induced by the studied
sPLA2. On the other hand, while inhibition of PPAR-γ
activation reduced LD formation, no modiﬁcation of
PLIN2 protein expression was observed, evidencing that
upon stimulus by MT-III, PPAR-γ and PPAR-β/δ regulate
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Figure 5: DGAT and ACAT enzymes are essential for LD formation induced by MT-III in macrophages. (a) Peritoneal macrophages were
incubated with A922500 (100 nM), a DGAT inhibitor or TMP-153 (100 nM), an ACAT inhibitor or vehicle (<1% DMSO/RPMI) for 1 h and
then with MT-III (0.4 μM) for 12 h. LDs were quantiﬁed using light microscopy after osmium staining. Each bar represents the mean± SEM
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LB formation by targeting diﬀerent genes related to lipid
uptake. This result contrasts with those demonstrating that
PPAR-γ regulates PLIN2 protein expression induced by
oxidized low-density lipoprotein or troglitazone, a PPAR-
γ agonist [36, 37]. Furthermore, the data here obtained
shows that MT-III is able to upregulate PPAR-γ and
PPAR-β/δ protein expression, underscoring an additional
mechanism by which this group IIA sPLA2 induces LD
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formation. In addition, our present results showed a
marked and early production of 15-d-PGJ2, which is
dependent on COX-1, but not COX-2 pathway. These
ﬁndings are in line with previous results showing that
MT-III induces an early increase of COX-1 activation in
macrophages [31]. On the other hand, upregulation of
COX-2 protein expression observed in macrophages stim-
ulated by MT-III may be related to biosynthesis of proin-
ﬂammatory prostaglandins, which were not investigated in
the present study, since inhibition of COX-2 did not aﬀect
MT-III-induced release of 15-d-PGJ2. This resolutive
mediator is recognized as a relevant activator of PPAR
family and has been found in macrophages of atheroscle-
rotic lesions [38]. Therefore, the tight correlation between
the proﬁles of 15-d-PGJ2 release and activation of PPARs
seen in the present study implicate 15-d-PGJ2 as an
important player in MT-III-induced activation of PPARs.
Moreover, our ﬁndings that MT-III caused an increase
of 15-d-PGJ2 intracellular pools colocalized to LDs in
MT-III-stimulated macrophages evidence that these
organelles are sites for production of 15-d-PGJ2. These
data are in accordance with previous reports on the
involvement of LDs in the production of inﬂammatory
mediators acting as a platform for enhanced synthesis of
lipid mediators. Taken together, these results give support
to our contention that these organelles are important sites
for 15-d-PGJ2 synthesis [39–42]. Although the mecha-
nisms involved in formation of 15-d-PGJ2 upon MT-III
stimulus were not presently investigated, we herein
hypothesize that, by providing a highly hydrophobic envi-
ronment, LDs are suitable sites for 15-d-PGJ2 production,
since this mediator is formed through the spontaneous
dehydration of PGD2 [38]. Additionally, our ﬁndings rein-
force the idea that LDs can also be implicated in the neg-
ative regulation of inﬂammatory response, as 15-d-PGJ2 is
a recognized preresolving mediator, signaling the switch
from acute inﬂammatory phase to the resolving phase of
inﬂammation [43, 44]. Hence, the formation of this medi-
ator upon the action of MT-III may reﬂect a regulatory
mechanism to dampen the inﬂammatory reaction elicited
by the enzyme.
In addition, our present results demonstrate that LD
formation induced by MT-III is largely dependent on the
endoplasmic reticulum enzymes DGAT and ACAT, since
inhibitors of their enzymatic activities abolished LD for-
mation induced by MT-III. Moreover, the increased levels
of TAG and CE detected under MT-III stimulation give
support to the participation of DGAT and ACAT in LD
formation induced by this sPLA2. Our data are in agree-
ment with ﬁndings that DGAT and ACAT are involved
in LD formation in a number of inﬂammatory conditions
[45–47]. PPAR-γ agonists have been described to induce
expression of DGAT and the consequent increase of triac-
ylglycerol storages [48]. However, gene expression of
DGAT and ACAT was not induced by MT-III in the pres-
ent experimental condition (data not shown)
Another PPAR-regulated factor relevant for LD forma-
tion in macrophages during atherogenic processes is the
receptor CD36 [49]. Our results demonstrating that inhibi-
tion of CD36 markedly reduced LD formation imply the
involvement of this scavenger receptor in foam cell forma-
tion induced by MT-III in macrophages. In support of this
ﬁnding, upregulation of CD36 protein expression by this
sPLA2 was observed. Moreover, our data showed that the
increased expression of this receptor induced by MT-III
is regulated by PPAR-β/δ and PPAR-γ, since inhibition
of these transcription factors abolished CD36 protein
expression. It is known that activation of the CD36 recep-
tor triggers a signaling pathway that leads to the synthesis
of inﬂammatory lipid mediators [27, 50]. Furthermore, the
observation that inhibition of CD36 downregulated COX-2
protein expression suggests a role for this receptor in the
formation of prostanoids in the late periods of activation
of macrophages induced by MT-III. Altogether, these ﬁnd-
ings emphasize the crucial role of PPAR-β/δ and PPAR-γ
for lipid accumulation in macrophages stimulated by
group IIA-sPLA2.
In conclusion, our data highlight the mechanisms
involved in LD formation induced by MT-III, a secreted
phospholipase A2 from snake venom (Figure 8). MT-III
was able to increase the expression of the transcription
factors PPAR-γ, PPAR-β/δ, and of the scavenger receptor
CD36 in peritoneal macrophages. Also, MT-III activated
these nuclear transcription factors. Inhibition of these
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Figure 7: MT-III-induced CD36 protein expression is dependent
on PPAR-γ and PPAR-β/δ activation. Peritoneal macrophages
were incubated with GW9662 (10 μM) or GSK0660 (10 μM)
compounds or vehicle (<1% DMSO/RPMI) for 1 h and then with
MT-III (0.4μM) for 6 h. Western blotting and densitometric
analysis of CD36 receptor and β-actin (loading control) in
macrophage extracts. The densities (in arbitrary units) were
normalized with those of β-actin. Results are expressed as mean
± SEM from three experiments. ∗p < 0 05 compared with controls;
#p < 0 05 compared with vehicle-treated MT-III-stimulated cells.
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factors as well as of CD36 and ACAT and DGAT enzymes
also reduced LD formation induced byMT-III, thus implicat-
ing these factors in LDs formation induced by PLA2 MT-III.
PPAR-β/δ, but not PPAR-γ, by inducing PLIN2 expression,
plays a key role in LD formation induced by MT-III. Both
transcription factors contribute to MT-III-induced CD36
protein expression. CD36 in turn regulated MT-III-induced
COX-2 protein expression. MT-III also induced formation
and release of 15-d-PGJ2, an activator of PPARs in macro-
phages. Therefore, LDs constitute a site for production of this
lipid mediator upon MT-III-induced stimulation. Consider-
ing the homology between mammalian-secreted phospholi-
pase A2 and phospholipase A2 found in snake venoms, our
results may contribute to the understanding of the actions
and mechanisms triggered by this class of enzymes related
to lipid accumulation in phagocytic cells in a variety of
inﬂammatory and pathological conditions.
Additional Points
Summary Statement. Lipid droplet formation induced by a
snake venom GIIA sPLA2 in macrophages depends on
lipid metabolism factors mainly PPAR-γ and PPAR-β/δ,
providing new insights into mechanisms of macrophage
foam cell formation.
Conflicts of Interest
The authors declare that they have no conﬂicts of interest.
Acknowledgments
The authors would like to thank Renata Hage do Amaral
Hernandez for providing technical assistance, Dr. Henrique
Krambeck Rofatto (FAPESP 00/11624-5, Butantan Institute)
Nucleus
ER
AC
AT
DG
AT
DG
AT
AC
AT
AC
AT
AC
AT
LDs
CD36
COX-2
PGs
PGJ2
COX-1
LDs
PLIN2
PLIN2
PLIN2
Cytoplasm
Macrophage
MT-III
CD36MT-III
Free fatty acid
PPA
R-훽
PPA
R-훾
9 4
7
6
8
5
10
3
21
Figure 8: Schematic illustration of the mechanisms involved in foam cell formation induced by MT-III a GIIA snake venom sPLA2. (1) MT-
III by acting on cellular membrane of macrophages generates free fatty acids, which will be internalized by CD36 scavenger receptors;
(2) activation of C36 receptor leads to formation of (3) lipid droplets and (4) expression of COX-2. (5) MT-III induces production of
15-d-PGJ2 via COX-1 pathway (6). This mediator and free fatty acids activate the cytoplasmic transcription factors PPARs; (7) PLIN2,
scaﬀold protein for lipid droplet assembly, is under transcriptional control of PPAR-β/δ and favors the increase of (8) lipid droplet
formation. (9) Both PPAR-γ and PPAR-β/δ upregulate CD36 protein expression forming a positive loop for generation of lipid
droplets in macrophages. (10) MT-III also activates endoplasmic reticulum enzymes (DGAT and ACAT) crucial for formation of
lipid droplets.
11Mediators of Inﬂammation
for helping with the confocal laser scanning microscopy anal-
ysis, and Dr. Lanfranco Raniere Troncone (Butantan Insti-
tute) for language revision. This work was supported by
research grants from the Fundação de Amparo a Pesquisa
do Estado de Sao Paulo (FAPESP; Brazil, Grants 2011/
21341-5 and 2014/18549-1). Elbio Leiguez was a recipient
of a PhD fellowship from FAPESP (Grant 2010/06345-1)
and is a recipient of a postdoctoral fellowship from FAPESP
(Grant 2015/24701-3); Karina Cristina Giannotti is a recipi-
ent of a PhD fellowship from FAPESP (Grant 2013/22610-
5); Mariana do Nascimento Viana is a recipient of a PhD fel-
lowship from CAPES; Márcio Hideki Matsubara is a recipi-
ent of PhD fellowship from FAPESP-Brazil (Grant 2010/
08506-2); Catarina Teixeira is a recipient of a PQ-CNPq
(Grant 307379/2016-7).
References
[1] G. Lambeau and M. H. Gelb, “Biochemistry and physiology of
mammalian secreted phospholipases A2,” Annual Review of
Biochemistry, vol. 77, no. 1, pp. 495–520, 2008.
[2] M. Murakami, Y. Taketomi, Y. Miki, H. Sato, K. Yamamoto,
and G. Lambeau, “Emerging roles of secreted phospholipase
A2 enzymes: the 3rd edition,” Biochimie, vol. 107, pp. 105–
113, 2014.
[3] D. A. Six and E. A. Dennis, “The expanding superfamily of
phospholipase A2 enzymes: classiﬁcation and characteriza-
tion,” Biochimica et Biophysica Acta (BBA) - Molecular and
Cell Biology of Lipids, vol. 1488, no. 1-2, pp. 1–19, 2000.
[4] F. Tonello and M. Rigoni, “Cellular mechanisms of action of
snake phospholipase A2 toxins,” in Snake Venoms, Toxinol-
ogy, P. Gopalakrishnakone, H. Inagaki, A. Mukherjee, T.
Rahmy, and C. W. Vogel, Eds., pp. 1–14, Springer, Dordrecht,
2015.
[5] A. Paul, B. H. J. Chang, L. Li, V. K. Yechoor, and L. Chan,
“Deﬁciency of adipose diﬀerentiation-related protein impairs
foam cell formation and protects against atherosclerosis,” Cir-
culation Research, vol. 102, no. 12, pp. 1492–1501, 2008.
[6] L. Becker, S. A. Gharib, A. D. Irwin et al., “A macrophage
sterol-responsive network linked to atherogenesis,” Cell
Metabolism, vol. 11, no. 2, pp. 125–135, 2010.
[7] J. Plakkal Ayyappan, A. Paul, and Y. H. Goo, “Lipid droplet-
associated proteins in atherosclerosis (review),” Molecular
Medicine Reports, vol. 13, no. 6, pp. 4527–4534, 2016.
[8] G. Onal, O. Kutlu, D. Gozuacik, and S. Dokmeci Emre, “Lipid
droplets in health and disease,” Lipids in Health and Disease,
vol. 16, no. 1, p. 128, 2017.
[9] M. A. Welte and A. P. Gould, “Lipid droplet functions beyond
energy storage,” Biochimica et Biophysica Acta (BBA) - Molec-
ular and Cell Biology of Lipids, vol. 1862, no. 10, Part B,
pp. 1260–1272, 2017.
[10] T. Araújo-Santos, D. B. Prates, B. B. Andrade et al., “Lutzo-
myia longipalpis saliva triggers lipid body formation and pros-
taglandin E2 production in murine macrophages,” PLoS
Neglected Tropical Diseases, vol. 4, no. 11, article e873, 2010.
[11] A. Nakata, Y. Nakagawa, M. Nishida et al., “CD36, a novel
receptor for oxidized low-density lipoproteins, is highly
expressed on lipid-laden macrophages in human atheroscle-
rotic aorta,” Arteriosclerosis, Thrombosis, and Vascular Biol-
ogy, vol. 19, no. 5, pp. 1333–1339, 1999.
[12] M. Febbraio, E. A. Podrez, J. D. Smith et al., “Targeted disrup-
tion of the class B scavenger receptor CD36 protects against
atherosclerotic lesion development in mice,” The Journal of
Clinical Investigation, vol. 105, no. 8, pp. 1049–1056, 2000.
[13] D. J. Rader and E. Puré, “Lipoproteins, macrophage function,
and atherosclerosis: beyond the foam cell?,” Cell Metabolism,
vol. 1, no. 4, pp. 223–230, 2005.
[14] T. C. Walther and R. V. Farese Jr., “Lipid droplets and cellular
lipid metabolism,” Annual Review of Biochemistry, vol. 81,
no. 1, pp. 687–714, 2012.
[15] J. M. Gutierrez and B. Lomonte, “Phospholipase A2 myotoxins
from Bothrops snake venoms,” Toxicon, vol. 33, pp. 1405–
1424, 1995.
[16] K. Takayama, D. H. Mitchell, Z. Z. Din, P. Mukerjee, C. Li, and
D. L. Coleman, “Monomeric re lipopolysaccharide from
Escherichia coli is more active than the aggregated form in
the Limulus amebocyte lysate assay and in inducing Egr-1
mRNA in murine peritoneal macrophages,” Journal of Biolog-
ical Chemistry, vol. 269, no. 3, pp. 2241–2244, 1994.
[17] E. Leiguez, K. C. Giannotti, V. Moreira et al., “Critical role of
TLR2 and MyD88 for functional response of macrophages to
a Group IIA-secreted phospholipase A2 from snake venom,”
PLoS One, vol. 9, no. 4, article e93741, 2014.
[18] C. Bandeira-Melo, P. F. Weller, and P. T. Bozza, “EicosaCell –
an immunoﬂuorescent-based assay to localize newly synthe-
sized eicosanoid lipid mediators at intracellular sites,” in Light
Microscopy, H. Chiarini-Garcia and R. Melo, Eds., vol. 689 of
Methods in Molecular Biology (Methods and Protocols),
pp. 163–181, Humana Press, Totowa, NJ, USA, 2011.
[19] T. Varga, Z. Czimmerer, and L. Nagy, “PPARs are a unique set
of fatty acid regulated transcription factors controlling both
lipid metabolism and inﬂammation,” Biochimica et Biophysica
Acta (BBA) - Molecular Basis of Disease, vol. 1812, no. 8,
pp. 1007–1022, 2011.
[20] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M.
Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostagalan-
din J2 is a ligand for the adipocyte determination factor
PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995.
[21] S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C.
Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite
binds peroxisome proliferator-activated receptor γ and pro-
motes adipocyte diﬀerentiation,” Cell, vol. 83, no. 5,
pp. 813–819, 1995.
[22] P. G. Blanchard, V. Turcotte, M. Côté et al., “Peroxisome
proliferator-activated receptor γ activation favours selective
subcutaneous lipid deposition by coordinately regulating
lipoprotein lipase modulators, fatty acid transporters and
lipogenic enzymes,” Acta Physiologica, vol. 217, no. 3,
pp. 227–239, 2016.
[23] N. Khelef, X. Buton, N. Beatini et al., “Immunolocalization of
acyl-coenzyme A: cholesterol O-acyltransferase in macro-
phages,” Journal of Biological Chemistry, vol. 273, no. 18,
pp. 11218–11224, 1998.
[24] S. J. Stone, H. M. Myers, S. M. Watkins et al., “Lipopenia and
skin barrier abnormalities in DGAT2-deﬁcient mice,” Journal
of Biological Chemistry, vol. 279, no. 12, pp. 11767–11776,
2004.
[25] H. Y. Huh, S. F. Pearce, L. M. Yesner, J. L. Schindler, and R. L.
Silverstein, “Regulated expression of CD36 during monocyte-
to-macrophage diﬀerentiation: potential role of CD36 in foam
cell formation,” Blood, vol. 87, no. 5, pp. 2020–2028, 1996.
12 Mediators of Inﬂammation
[26] Y. M. Park, “CD36, a scavenger receptor implicated in athero-
sclerosis,” Experimental & Molecular Medicine, vol. 46, no. 6,
article e99, 2014.
[27] K. Bujold, D. Rhainds, C. Jossart, M. Febbraio, S. Marleau, and
H. Ong, “CD36-mediated cholesterol eﬄux is associated with
PPARγ activation via a MAPK-dependent COX-2 pathway
in macrophages,” Cardiovascular Research, vol. 83, no. 3,
pp. 457–464, 2009.
[28] P. Libby, M. DiCarli, and R. Weissleder, “The vascular biology
of atherosclerosis and imaging targets,” The Journal of Nuclear
Medicine, vol. 51, Supplement_1, pp. 33S–37S, 2010.
[29] B. Desvergne and W. Wahli, “Peroxisome proliferator-
activated receptors: nuclear control of metabolism,” Endocrine
Reviews, vol. 20, no. 5, pp. 649–688, 1999.
[30] M. Alaoui-El-Azher, Y. Wu, N. Havet et al., “Arachidonic acid
diﬀerentially aﬀects basal and lipopolysaccharide-induced
sPLA2-IIA expression in alveolar macrophages through NF-
κB and PPAR-γ-dependent pathways,” Molecular Pharmacol-
ogy, vol. 61, no. 4, pp. 786–794, 2002.
[31] V. Moreira, J. M. Gutiérrez, A. M. Soares, S. R. Zamunér,
E. Purgatto, and C. . F. P. Teixeira, “Secretory phospholipases
A2 isolated from Bothrops asper and from Crotalus durissus
terriﬁcus snake venoms induce distinct mechanisms for bio-
synthesis of prostaglandins E2 and D2 and expression of
cyclooxygenases,” Toxicon, vol. 52, no. 3, pp. 428–439, 2008.
[32] D. Namgaladze, D. Morbitzer, A. von Knethen, and B. Brune,
“Phospholipase A2–modiﬁed low-density lipoprotein activates
macrophage peroxisome proliferator–activated receptors,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30,
no. 2, pp. 313–320, 2010.
[33] H. Vosper, L. Patel, T. L. Graham et al., “The peroxisome
proliferator-activated receptor δ promotes lipid accumulation
in human macrophages,” Journal of Biological Chemistry,
vol. 276, no. 47, pp. 44258–44265, 2001.
[34] S. E. Schadinger, N. L. Bucher, B. M. Schreiber, and S. R.
Farmer, “PPARγ2 regulates lipogenesis and lipid accumula-
tion in steatotic hepatocytes,” American Journal of Physiology
Endocrinology and Metabolism, vol. 288, no. 6, pp. e1195–
e1205, 2005.
[35] P. E. Almeida, A. R. Silva, C. M. Maya-Monteiro et al., “Myco-
bacterium bovis bacillus Calmette-Guérin infection induces
TLR2-dependent peroxisome proliferator-activated receptor
γ expression and activation: functions in inﬂammation, lipid
metabolism, and pathogenesis,” The Journal of Immunology,
vol. 183, no. 2, pp. 1337–1345, 2009.
[36] W. Motomura, M. Inoue, T. Ohtake et al., “Up-regulation of
ADRP in fatty liver in human and liver steatosis in mice fed
with high fat diet,” Biochemical and Biophysical Research Com-
munications, vol. 340, no. 4, pp. 1111–1118, 2006.
[37] Q. Liu, Z. Dai, Z. Liu et al., “Oxidized low-density lipoprotein
activates adipophilin through ERK1/2 signal pathway in
RAW264.7 cells,” Acta Biochimica et Biophysica Sinica,
vol. 42, no. 9, pp. 635–645, 2010.
[38] T. Shibata, M. Kondo, T. Osawa, N. Shibata, M. Kobayashi,
and K. Uchida, “15-deoxy-Δ12,14-prostaglandin J2 a prosta-
glandin D2 metabolite generated during inﬂammatory pro-
cesses,” Journal of Biological Chemistry, vol. 277, no. 12,
pp. 10459–10466, 2002.
[39] M. T. Accioly, P. Pacheco, C. M. Maya-Monteiro et al., “Lipid
bodies are reservoirs of cyclooxygenase-2 and sites of prosta-
glandin-E2 synthesis in colon cancer cells,” Cancer Cells,
vol. 68, no. 6, pp. 1732–1740, 2008.
[40] H. D'Avila, N. R. Roque, R. M. Cardoso, H. C. Castro-Faria-
Neto, R. C. N. Melo, and P. T. Bozza, “Neutrophils recruited
to the site ofMycobacterium bovis BCG infection undergo apo-
ptosis and modulate lipid body biogenesis and prostaglandin
E2 production by macrophages,” Cellular Microbiology,
vol. 10, no. 12, pp. 2589–2604, 2008.
[41] P. T. Bozza, K. G. Magalhães, and P. F. Weller, “Leukocyte
lipid bodies— biogenesis and functions in inﬂammation,” Bio-
chimica et Biophysica Acta (BBA) - Molecular and Cell Biology
of Lipids, vol. 1791, no. 6, pp. 540–551, 2009.
[42] K. C. Giannotti, E. Leiguez, A. E. Z. Carvalho et al., “A snake
venom group IIA PLA2 with immunomodulatory activity
induces formation of lipid droplets containing 15-d-PGJ2 in
macrophages,” Scientiﬁc Reports, vol. 7, no. 1, article 4098,
2017.
[43] J. U. Scher and M. H. Pillinger, “15d-PGJ2: the anti-
inﬂammatory prostaglandin?,” Clinical Immunology, vol. 114,
no. 2, pp. 100–109, 2005.
[44] M. Hilliard, C. Frohnert, C. Spillner et al., “The anti-
inﬂammatory prostaglandin 15-deoxy-Δ12,14-PGJ2 inhibits
CRM1-dependent nuclear protein export,” Journal of Biologi-
cal Chemistry, vol. 285, no. 29, pp. 22202–22210, 2010.
[45] F. Quittnat, Y. Nishikawa, T. T. Stedman et al., “On the bio-
genesis of lipid bodies in ancient eukaryotes: synthesis of triac-
ylglycerols by a toxoplasma DGAT1-related enzyme,”
Molecular and Biochemical Parasitology, vol. 138, no. 1,
pp. 107–122, 2004.
[46] D. Matsuda, T. Ohshiro, M. Ohba et al., “The molecular target
of rubimaillin in the inhibition of lipid droplet accumulation
in macrophages,” Biological and Pharmaceutical Bulletin,
vol. 32, no. 8, pp. 1317–1320, 2009.
[47] P. J. McFie, S. L. Banman, S. Kary, and S. J. Stone, “Murine
diacylglycerol acyltransferase-2 (DGAT2) can catalyze triacyl-
glycerol synthesis and promote lipid droplet formation inde-
pendent of its localization to the endoplasmic reticulum,”
Journal of Biological Chemistry, vol. 286, no. 32, pp. 28235–
28246, 2011.
[48] S. K. Koliwad, R. S. Streeper, M. Monetti et al., “DGAT1-
dependent triacylglycerol storage by macrophages protects
mice from diet-induced insulin resistance and inﬂammation,”
The Journal of Clinical Investigation, vol. 120, no. 3, pp. 756–
767, 2010.
[49] T. S. Lee, C. Y. Lin, J. Y. Tsai et al., “Resistin increases lipid
accumulation by aﬀecting class A scavenger receptor, CD36
and ATP-binding cassette transporter-A1 in macrophages,”
Life Sciences, vol. 84, no. 3-4, pp. 97–104, 2009.
[50] O. Kuda, C. M. Jenkins, J. R. Skinner et al., “CD36 protein is
involved in store-operated calcium ﬂux, phospholipase A2
activation, and production of prostaglandin E2,” Journal of
Biological Chemistry, vol. 286, no. 20, pp. 17785–17795, 2011.
13Mediators of Inﬂammation
